^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | PT217 (CD47 inhibitor, DLL3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA
Published date:
04/08/2024
Excerpt:
...U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
